NEW YORK (AP) — Twitter has unsealed the documents for its planned initial public offering of stock and says it hopes to raise up to $1 billion.
The company is also disclosing that it generated $317 million in revenue in 2012 and that it has more than 215 million active users. That compares with Facebook's nearly 1.2 billion and LinkedIn's 240 million.
The company disclosed last month that it had filed confidential IPO papers to start the process of going public. On Thursday, San Francisco-based Twitter Inc. unsealed the papers with the Securities and Exchange Commission.
Twitter's moneymaking potential has minted the company with an estimated market value of $10 billion, based on the appraisals of venture capitalists and other early investors. The IPO could value it higher or lower.
Twitter did not say which stock exchange it plans to list its shares on, though the company said it intends to use the ticker symbol "TWTR."
The underwriters of the offering are Goldman Sachs, Morgan Stanley, JP Morgan, BofA Merrill Lynch, Deutsche Bank Securities and CODE Advisors.
Best Semiconductor Stocks To Buy Right Now: American Axle & Manufacturing Holdings Inc. (AXL)
American Axle & Manufacturing Holdings, Inc., together with its subsidiaries, engages in the manufacture, engineering, design, and validation of driveline and drivetrain systems, and related components and chassis modules for automotive industry in the United States. The company?s driveline and drivetrain systems comprise components that transfer power from the transmission and deliver it to the drive wheels. These products include axles, chassis modules, driveshafts, power transfer units, transfer cases, chassis and steering components, driving heads, crankshafts, transmission parts, and metal-formed products. It offers products for light trucks, sport utility vehicles, passenger cars, crossover vehicles, and commercial vehicles. The company was founded in 1994 and is headquartered in Detroit, Michigan.
Advisors' Opinion:- [By Sue Chang]
American Axle & Manufacturing Holdings Inc. (AXL) �is projected to report earnings of 56 cents a share in the third quarter.
Top 5 Consumer Service Stocks To Buy Right Now: Syntroleum Corporation(SYNM)
Syntroleum Corporation and its subsidiaries engage in commercializing and licensing its Syntroleum technologies to produce synthetic liquid hydrocarbons. Its Syntroleum process involves conversion of carbon containing material into synthesis gas; and conversion of the synthesis gas or coal-derived or biomass-derived syngas into hydrocarbons. The company also develops the Synfining Process technology for the conversion of Fischer-Tropsch wax into various products, including diesel fuels, jet fuels, lubricants, naphtha, and other materials. In addition, it offers the Bio-Synfining technology, a second generation renewable fuels technology that is feedstock flexible, including the use of vegetable oils, fats, fatty acids, and greases. Syntroleum Corporation was founded in 1984 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By John Udovich]
Small cap biofuel or synthetic fuel stocks Gevo, Inc (NASDAQ: GEVO), KiOR Inc (NASDAQ: KIOR), Solazyme Inc (NASDAQ: SZYM) and Syntroleum Corp (NASDAQ: SYNM) all seem to have been seeing some trading action in recent days���meaning its worth taking a closer look at all four�before taking a look at their rather dismal�long term performance while noting that none are yet profitable:
- [By John Udovich]
As a new Government Accountability Office (GAO) report comes out about wasteful spending on biofuels, small cap renewable biofuel stock Gevo, Inc (NASDAQ: GEVO) reported earnings that came in below expectations -�meaning its worth taking a closer look at the GAO report, the stock and the performance of KiOR Inc (NASDAQ: KIOR), Solazyme Inc (NASDAQ: SZYM) and Syntroleum Corp (NASDAQ: SYNM).
Top 5 Consumer Service Stocks To Buy Right Now: Camden Property Trust (CPT)
Camden Property Trust is a real estate investment trust (REIT). The Company is engaged in the ownership, management, development, acquisition, and construction of multi-family apartment communities. As each of its communities has similar economic characteristics, residents, amenities, and services, its operations have been aggregated into one segment.
In April 2011, it sold one of its land parcels to one of the Funds. In June 2011, it sold another land parcel to the Fund. In August 2011, the Company acquired 30.1 acres of land located in Atlanta, Georgia. In December 2011, it acquired 2.2 acres of land in Glendale, California. During the year ended December 31, 2011, it sold two properties consisting of 788 units located in Dallas, Texas. During 2011, the Funds acquired 18 multifamily properties totaling 6,076 units located in the Houston, Dallas, Austin, San Antonio, Tampa and Atlanta. In January 2012, one of the Funds acquired one multifamily property consisted of 350 units located in Raleigh, North Carolina.
As of December 31, 2011, the Company owned interests in, operated, or were developing 206 multifamily properties comprising 69,794 apartment homes across the United States. Of these 206 properties, 10 properties were under development. In addition, it owns land parcels, which it focuses on developing into multifamily apartment communities.
Advisors' Opinion:- [By Michael Lewis]
Take Camden Property Trust (NYSE: CPT ) , for example. The stock is up around 16% over two years -- respectable, but incongruent with the industry trends. Since 2010, operating cash flow has increased more than 30%. The company pays a 3.5% dividend and trades at 16.5 times projected one-year earnings. For comparison, Lennar trades at 18 times earnings, while KB Homes trades at more than 20 times forward earnings.
Top 5 Consumer Service Stocks To Buy Right Now: Alexion Pharmaceuticals Inc.(ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products for treating patients with severe and life-threatening disease states in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, neurology, ophthalmology, and cancer. The company develops and commercializes Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It also conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; atypical hemolytic uremic syndrome; presensitized renal transplant; kidney transplant for catastrophic antiphospholipid syndrome; ABO incompatible renal transplant; dense deposit disease; myasthenia gravis; neuromyelitis optica; and dry a ge-related macular degeneration. In addition, the company conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry; and Phase I clinical trails on Samalizumab for the treatment of oncology diseases, such as chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals, Inc. serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.
Advisors' Opinion:- [By Ben Levisohn]
Stocks fell today despite the lack of anything significant that would drive down the prices of Netflix (NFLX), Alexion Pharmaceuticals (ALXN) and Facebook (FB), among other high fliers.
- [By Dan Carroll]
Connecticut has also forged its share of innovative firms, with Alexion Pharmaceuticals (NASDAQ: ALXN ) a standard-bearer in that regard. Alexion earned its big breakthrough with its orphan drug Soliris, a treatment for an ultra-rare cause of anemia that has emerged as a blockbuster for this small firm. Alexion recently earned another orphan drug designation for a new experimental therapy under development, keeping this company at the forefront of Connecticut's innovative edge -- an edge that has fueled this state's wealth.
No comments:
Post a Comment